From Lab to GMP: A CFO Framework for Comparing CDMOs, Cleanroom Rental, and BMEOs

Executive Summary 

For preclinical and Phase I biopharma companies, the move from the research lab into a GMP environment is not just a manufacturing decision. It is a capital allocation decision. It determines how much cash is tied up before clinical proof of concept, how much operational risk management accepts, how much control the company retains over its process, and how credible the development plan appears to investors, partners, and the board. 

Most early-stage companies have three practical choices: hire a contract development and manufacturing organization (CDMO), rent cleanroom space and operate it themselves, or use a Biomanufacturing Enablement Organization (BMEO) model that combines facility access with the necessary operating support. For a CFO or CEO, the question is not which option looks cheapest in a proposal. The question is which option gives the company the highest probability of reaching the next value-creating milestone with the least avoidable dilution, delay, stranded cost, and execution risk. 

This paper provides a CFO-oriented framework for comparing CDMOs, cleanroom rental, and Biomanufacturing Enablement Organization (BMEO) models across the dimensions that matter most to leadership teams: total milestone cost, cash runway, fixed versus variable commitments, specialized equipment needs, quality responsibility, operational control, IP exposure, timeline risk, investor perception, and downside protection if the program changes direction. 

The Decision Is Bigger Than “Where Do We Make It?” 

When a company leaves the research lab and enters a GMP environment, it is crossing a threshold. The work becomes more structured, more documented, more visible to regulators and investors, and more dependent on disciplined execution. The company must decide who owns the process, who controls the timeline, who maintains the quality system, who manages materials and equipment, and who is accountable when the plan changes. 

For Phase I investigational drugs, FDA guidance recognizes that early clinical manufacturing should be risk-based and appropriate to the scale and purpose of the trial, while still protecting patient safety and product quality. That flexibility is valuable, but it does not eliminate the need for personnel, facilities, equipment, controls, records, QC oversight, stability planning, and appropriate handling of biological or aseptic processing risks. The challenge for startups is building enough GMP discipline to support clinical progress without prematurely creating the cost structure of a later-stage manufacturer. 

The right model should match the company’s stage, modality, team, funding position, technical complexity, and desired level of control. A virtual biotech with no internal manufacturing experience may need a different answer than a founder-led cell therapy company that wants hands-on control of its process. A program preparing for toxicology supply may need a different model than a program preparing for recurring Phase I patient manufacturing. 

The Three Practical Paths

Option 1: Hire a CDMO 

A CDMO can provide development, manufacturing, quality, regulatory support, specialized equipment, experienced personnel, and an established GMP facility. For CFOs, one of the most important advantages is that the CDMO may already own expensive or difficult-to-source manufacturing equipment that the startup would otherwise need to purchase, lease, qualify, maintain, insure, and eventually write off if the program changes. This can be especially important for specialized bioreactors, isolators, fill-finish equipment, closed processing systems, automated cell processing platforms, chromatography skids, lyophilizers, or modality-specific analytical equipment. 

The tradeoff is that the sponsor may lose direct control over scheduling, personnel, process decisions, and day-to-day manufacturing execution. Technology transfer can take months, queue times can be significant, and changes may trigger additional scope, change orders, or delays. For complex biologics, cell therapies, tissue-derived products, autologous workflows, or novel processes, the “fit” between the sponsor’s process and the CDMO’s operating model can matter more than the CDMO’s general GMP credentials. 

That equipment advantage should be weighed against utilization, access, and fit. Equipment that exists at a CDMO is valuable only if it is available when needed, appropriate for the sponsor’s process, properly qualified for the intended use, and not tied to scheduling constraints that slow the program. Conversely, buying specialized equipment for a rented cleanroom can create control and learning advantages, but it can also create stranded capital if the asset is underutilized, becomes obsolete, fails to support a process change, or cannot be transferred easily to the next facility. 

Option 2: Rent Cleanroom Space 

Cleanroom rental gives a company access to physical GMP-capable space without building its own facility. It can be faster and less capital-intensive than constructing dedicated infrastructure. It may also allow the sponsor to keep more direct control over its process, people, equipment, and IP. For companies with experienced internal manufacturing, quality, and operations leadership, this can be an effective bridge from the lab to clinical supply. 

The risk is that rent is only one part of the cost. The company still needs to define the quality model, qualify equipment, manage materials, train personnel, establish documentation, handle cleaning and environmental monitoring responsibilities, coordinate IT and data controls, and ensure the space is fit for its intended use. In other words, cleanroom rental can solve the real estate problem without fully solving the GMP operating problem. 

Option 3: Use a Biomanufacturing Enablement Organization (BMEO) 

A Biomanufacturing Enablement Organization (BMEO) sits between traditional outsourcing and basic cleanroom rental. It typically combines GMP-ready space with selected operating support such as quality-system access, project management, environmental monitoring, cleaning, materials support, readiness consulting, and facility operations. The purpose is to give an emerging company a structured path into GMP without requiring it to build a facility or transfer the entire process to an external manufacturer.

 

 Side-by-Side Comparison

 

Decision Factor	CDMO	Cleanroom Rental	BMEO
Best fit	Companies that want to outsource manufacturing execution and rely on an external operator.	Companies with internal GMP leadership and the ability to build their own operating layer.	Emerging companies that want control of the process with integrated GMP infrastructure and readiness support.
Upfront capital	Lower than building, but tech transfer, reservation fees, development work, and batch costs can be significant.	Lower than building, but equipment, qualification, staffing, quality systems, materials handling, and support costs remain.	Bundled or semi-bundled model designed to reduce upfront complexity and avoid major facility capital investment.
Timeline	Can be fast if capacity is available and the process fits; can be delayed by queue time and technology transfer.	Can be faster than building, but readiness depends on the sponsor’s ability to qualify, staff, and operate the space.	Can provide a structured onboarding path into GMP readiness and early clinical manufacturing if the scope is well defined.
Control	Lower direct control over personnel, schedule, execution, and process handling.	High control, but high responsibility.	High sponsor control over product and process, with infrastructure and operating support from the facility provider.
Quality burden	CDMO quality system carries much of the operational burden, subject to quality agreement and sponsor oversight.	Sponsor must establish or adapt a quality model and manage many GMP responsibilities directly.	Provides access to an established GMP operating environment, documentation support, readiness consulting, and defined responsibility boundaries.
IP exposure	Requires deeper transfer of process knowledge to an outside manufacturing counterparty.	Sponsor keeps process execution closer to its own team.	Sponsor maintains process ownership while using third-party infrastructure and support.
Scalability	Can scale if CDMO capacity exists and commercial strategy aligns.	Scales only if additional space, staff, equipment, and systems can be added.	May support phased progression if the provider offers additional space, services, or operating support as needs evolve.
Main risk	Loss of control, queue delays, tech transfer friction, change order growth, and strategic dependency.	Underestimating the operating burden hidden behind the monthly rent.	Requires clear alignment on sponsor responsibilities, scope boundaries, and what remains product-specific.

 

The Full Cost Stack 

The most common mistake in lab-to-GMP planning is comparing incomplete numbers. A CDMO quote, a cleanroom rental rate, and a bundled or semi-bundled infrastructure price are not the same type of number. A CFO should normalize each option to the same milestone: toxicology material, IND submission readiness, first GMP batch, first patient, Phase I supply, or a specified number of manufacturing campaigns. The analysis should distinguish cash costs, committed costs, internal labor, third-party services, capital equipment, depreciation or write-off exposure, and risk-adjusted delay costs. 

Cost Checklist: Included, Excluded, or Variable by Model 

Cost or Responsibility	CDMO	Cleanroom Rental	BMEO
GMP facility access	Generally included in batch or program pricing.	Included as space rental only.	Included if facility access is part of the model; scope should be confirmed.
Specialized manufacturing equipment	Often included if the CDMO has the right equipment and available capacity.	Usually excluded; sponsor may need to buy, lease, move, qualify, maintain, and insure equipment.	Variable; platform equipment and support may be available, but product-specific equipment should be confirmed in scope.
Equipment qualification, calibration, and maintenance	Often included for CDMO-owned equipment, subject to scope and quality agreement.	Usually sponsor responsibility unless separately contracted.	Partly included or supported depending on equipment ownership and agreed scope.
Technology transfer and process fit work	Usually charged separately or embedded in development fees.	Sponsor responsibility.	May be supported through onboarding and readiness work, but product-specific process development usually remains sponsor responsibility.
Manufacturing operators	Included if CDMO executes manufacturing.	Excluded unless labor is separately contracted.	Variable; sponsor execution and provider support should be defined in the agreement.
Quality system and document control	CDMO system generally included, with sponsor oversight.	Usually sponsor responsibility.	May be included or supported for facility and operating infrastructure; product-specific quality responsibilities must be defined.
Environmental monitoring and cleaning	Generally included for CDMO-controlled areas.	Often excluded or separately charged.	May be included or supported as part of the GMP operating environment, subject to scope.
Materials management and storage	Included or charged through pass-through and handling fees.	Usually sponsor responsibility.	May be supported or included depending on storage type, chain of custody, and material handling requirements.
Internal management time	Lower operational burden, but sponsor oversight remains necessary.	High; sponsor must manage the operating model.	Moderate; sponsor retains control but receives infrastructure and project support.
Idle capacity or underutilization risk	Lower equipment ownership risk, but reservation or cancellation fees may apply.	High if space or equipment is committed before the program is ready.	Lower than self-build or pure rental if commitments are matched to milestone-based needs.
Change orders and scope creep	Common risk as the process evolves.	Less vendor-driven, but sponsor absorbs the cost directly.	Managed through clear scoping; changes should be tied to defined responsibilities.
Exit cost if program pauses or fails	Contract termination, cancellation fees, and tech transfer sunk cost.	Lease obligations, equipment resale loss, decommissioning, and stranded staff or consultants.	Depends on contract structure, but may be lower than a self-build or equipment-heavy rental model.

 

Cost Categories to Include 

• Facility access, rent, reservation fees, or occupancy charges. 

• Technology transfer, process mapping, facility fit assessments, and documentation conversion. 

• Equipment purchase, movement, installation, qualification, calibration, and maintenance. 

• Environmental monitoring, cleaning, disinfection, pest control, and excursion investigations. 

• Quality systems, document control, training, deviations, CAPA, supplier qualification, and audit readiness. 

• Materials management, cold storage, quarantine, kitting, chain of custody, waste handling, and shipping. 

• Personnel costs, including manufacturing operators, quality, QC, facilities, supply chain, project management, and consultants. 

• IT, data integrity, network access, security, electronic records, and system validation where applicable. 

• Schedule risk, idle time, failed batches, rework, change orders, and opportunity cost of delay. 

• Investor and board impact, including dilution from raising capital to fund infrastructure rather than clinical milestones. 

Specialized equipment deserves separate CFO scrutiny. If the CDMO already has the required equipment, the company may avoid a large capital purchase and the operational burden of qualification, maintenance, calibration, spare parts, service contracts, and eventual disposition. If the company rents cleanroom space and buys equipment, the financial model should include not only purchase price but installation, validation, downtime, insurance, depreciation, resale uncertainty, and whether the equipment will still be useful if the process changes between preclinical, Phase I, and later-stage manufacturing. 

For early-stage companies, the largest cost is often not the line item that appears largest in the quote. It is the cost of delay, underutilization, rework, or capital tied up in infrastructure before the program is de-risked. A model that looks more expensive on a monthly basis may be cheaper if it avoids a six-month delay, reduces failed readiness activities, or prevents a premature facility buildout. 

Benefits and Tradeoffs by Model 

CDMO: Benefits 

• Immediate access to experienced manufacturing personnel and established GMP systems. 

• Potentially strong fit for standardized platforms, known modalities, or companies without internal manufacturing capability. 

• Can reduce the need to hire a full internal GMP team early. 

• May provide integrated development, analytical, regulatory, packaging, or supply chain services. 

• Can be credible to investors if the CDMO has a strong track record in the relevant modality. 

CDMO: Tradeoffs 

• Less control over timing, staffing, execution details, and process decisions. 

• Technology transfer can be underestimated and may become a critical path item. 

• Change orders can grow as the process evolves or early assumptions prove incomplete. 

• IP and know-how must be shared more deeply with an outside manufacturing organization. 

• Batch scheduling and capacity may compete with larger or later-stage customers. 

• Switching CDMOs later can create additional technology transfer, comparability, and timeline risk. 

Cleanroom Rental: Benefits 

• More direct control over the process, personnel, equipment, schedule, and operating decisions. 

• Lower capital requirement than building a dedicated GMP facility. 

• Potentially faster access than construction if the space is available and appropriate. 

• Less need to transfer sensitive process knowledge to a CDMO. 

• Can support hands-on learning and internal manufacturing capability development. 

Cleanroom Rental: Tradeoffs 

• Rent does not equal readiness; the company must still build or manage the GMP operating system. 

• Requires experienced internal leadership across manufacturing, quality, facilities, materials, and compliance. 

• Hidden costs can include equipment qualification, cleaning, environmental monitoring, documentation, training, deviations, and consultant support. 

• The sponsor may carry idle-time costs if manufacturing is intermittent. 

• Regulatory and inspection readiness can become fragmented if responsibilities are not clearly defined. 

BMEO: Benefits 

• Can be well suited for emerging companies preparing for IND-enabling work and Phase I manufacturing. 

• May combine GMP-ready cleanroom access with onboarding, quality and regulatory readiness, project management, environmental monitoring, cleaning, equipment support, storage, and operational guidance. 

• Allows the sponsor to retain product ownership, process control, IP ownership, and regulatory strategy. 

• Reduces the burden of building an internal facility or creating an operating model from scratch. 

• Can improve investor readiness by showing a practical, capital-efficient path to first patient. 

• Provides a bridge between pure cleanroom rental and full manufacturing outsourcing. 

• May support phased growth if the provider offers additional infrastructure or services as the company advances beyond Phase I. 

BMEO: Tradeoffs 

• The sponsor still remains responsible for product-specific decisions, manufacturing execution, regulatory submissions, product approvals, and product ownership. 

• The model requires clear scoping so both parties understand what is included, what is optional, and what requires a change order. 

• Companies that want to outsource all manufacturing execution may still prefer a CDMO. 

• Companies with a mature internal GMP organization may not need a bundled support model. 

Decision Framework: Which Model Fits Best?

 

If the company’s priority is…	Most likely fit	Why
Full outsourcing of manufacturing execution	CDMO	The sponsor wants an external party to run the process under its own GMP operating model.
Maximum process control with an experienced internal GMP team	Cleanroom rental	The sponsor can manage quality, equipment, staffing, materials, documentation, and readiness directly.
Control plus support for first patient readiness	BMEO	The sponsor wants to keep ownership and control while accessing GMP infrastructure, systems, and operational guidance.
Fastest route without building a facility	Depends on process fit	A CDMO may be fastest if already aligned; a BMEO may be faster if technology transfer to a CDMO would create delays.
Lowest apparent monthly cost	Usually cleanroom rental	But apparent rent must be adjusted for all hidden operating, quality, staffing, and readiness costs.
Lowest total milestone cost	Case-specific	The correct answer depends on total cost to reach toxicology supply, IND readiness, first GMP batch, or first patient.
IP protection and learning retention	Cleanroom rental or BMEO	Both allow the sponsor to keep more know-how inside its own team than a traditional CDMO transfer.
Investor confidence in capital efficiency	CDMO or BMEO	Both can show that the company is avoiding premature facility CapEx; a BMEO adds a control-oriented operating story.

Questions Every Startup Should Ask Before Choosing 

Program and Process 

• What exact milestone are we trying to reach: toxicology material, IND submission, first GMP batch, first patient, or recurring Phase I supply? 

• How mature is the process, and how likely is it to change before or during Phase I? 

• Does the process require specialized equipment, open processing, aseptic manipulation, viral vector handling, cell therapy workflows, tissue processing, or unique containment? 

• How much process knowledge are we willing to transfer externally? 

• What would happen if the first GMP run fails or the clinical timeline shifts by six months? 

Equipment and CapEx 

• What specialized manufacturing or analytical equipment is required for the process? 

• Is the equipment already available at a CDMO, a flexible GMP infrastructure provider, or another GMP-capable site? 

• Is the equipment already available at a CDMO, a BMEO, or another GMP-capable site? 

• Will the equipment be fully utilized, or will it sit idle between campaigns? 

• Can the equipment be moved, resold, repurposed, or transferred if the program changes? 

• Would equipment ownership improve process control enough to justify the stranded-capital risk? 

Quality and Regulatory 

• Who owns the quality system for each activity? 

• Who approves batch records, deviations, CAPA, training records, cleaning documentation, EM results, and material release decisions? 

• What will be covered in the quality agreement? 

• What documentation will support IND readiness and investor diligence? 

• How will facility qualification, equipment qualification, environmental monitoring, and cleaning responsibilities be divided? 

• What happens if a regulator or investor asks to inspect the operating model? 

Financial and Strategic 

• What is the total cost to reach the next value-creating milestone, not just the monthly or per-batch price? 

• How much cash runway is consumed before clinical data or another financing milestone? 

• What costs are fixed even if the program pauses? 

• How much dilution could be avoided by not building infrastructure prematurely? 

• Does the model improve or weaken the story to investors, partners, and the board? 

• What is the exit cost if the program fails, pivots, or changes modality? 

How to Compare the Economics Fairly 

A fair comparison should start with one defined scenario. For example: “What does it cost to manufacture Phase I clinical material for five patients within twelve months?” or “What does it cost to reach IND-ready GMP manufacturing capability for one autologous cell therapy program?” The scenario should specify whether specialized equipment is required, who owns it, whether it is already available, and how its cost is treated if the program pauses, fails, or scales. 

The comparison should include four layers: direct quoted costs, required add-on costs, internal personnel and consultant costs, and risk-adjusted costs. Risk-adjusted costs include likely delays, idle time, change orders, rework, failed readiness activities, equipment underutilization, stranded CapEx, and the strategic cost of tying up capital before the program is de-risked. 

For many early-stage companies, the best model is the one that preserves optionality. The company needs enough GMP infrastructure and discipline to reach the next milestone, but not so much fixed cost that it becomes trapped if the program changes. That is the central economic argument for BMEO models. 

AI Prompt for Building a Cost Comparison Model in Excel 

CFOs can use the following prompt in Copilot for Excel to create a first-pass financial model comparing CDMO outsourcing, cleanroom rental, and BMEO models. The output should be reviewed and customized before being used for board, investor, or vendor decisions. 

Create an Excel financial model comparing three options for moving a preclinical or Phase I biotech program from the lab into GMP manufacturing:
1) CDMO outsourcing
2) cleanroom rental with sponsor-managed operations
3) a Biomanufacturing Enablement Organization (BMEO) model.
Build the model around a defined milestone, such as IND readiness, first GMP batch, first patient, or Phase I clinical supply. Create separate input sections for program assumptions, manufacturing campaigns or batches, timeline by month, facility or CDMO fees, specialized equipment purchase or lease, equipment qualification, maintenance, calibration, service contracts, insurance, depreciation, resale value, stranded CapEx risk, technology transfer and process fit costs, internal personnel costs, external consultants and quality support, environmental monitoring, cleaning, utilities, waste, materials handling, QC testing, release testing, stability, analytical support, storage, cold chain, shipping, logistics, regulatory support, documentation, training, deviations, CAPA, audit readiness, change orders, delay costs, idle capacity, failed batch or rework assumptions, and termination or exit costs. For each option, calculate total cash cost to milestone, monthly cash burn, fixed versus variable cost, CapEx versus OpEx, internal FTE burden, risk-adjusted cost, estimated delay impact, exit cost if the program pauses or fails, and net impact on cash runway. Create summary tables and charts showing total cost by option, cash runway impact, CapEx exposure, fixed-cost commitments, sensitivity to delay, sensitivity to equipment utilization, sensitivity to number of batches or patients, and best-case, base-case, and downside-case scenarios. Include a dashboard that highlights the lowest quoted cost, lowest total milestone cost, lowest risk-adjusted cost, highest control option, lowest stranded-capital risk, and key assumptions that drive the decision. Use formulas, clearly labeled assumptions, and separate tabs for Inputs, Model, Sensitivities, Scenario Summary, and Dashboard. 

Where BMEO Fits 

A Biomanufacturing Enablement Organization (BMEO) is not simply a cheaper CDMO alternative or a more expensive cleanroom rental. It is a defined category: a manufacturing-readiness model for emerging companies that need infrastructure, quality support, operational guidance, and execution structure while retaining control of their product and process. The term BMEO distinguishes enablement from traditional outsourcing or space-only rental without tying the model to any single provider. 

The model is particularly relevant when a company has valuable internal process knowledge, needs to protect IP, wants to avoid CDMO queue risk, and is not ready to build its own facility. It is also relevant when the team needs help converting scientific readiness into manufacturing readiness: documentation, facility fit, quality alignment, training, environmental monitoring, materials flow, equipment placement, project governance, and investor-facing credibility. 

For preclinical and Phase I programs, a BMEO can be a practical middle ground: more control than a CDMO, more support than space rental, and less capital intensity than building. The value is not only the cleanroom. It is the operating path that helps an emerging company reach first patient without taking on infrastructure risk too early. 

Practical Recommendation 

Before selecting a model, every preclinical or Phase I company should build a milestone-based comparison across all three options. The analysis should not ask, “Which quote is lowest?” It should ask, “Which path gives us the highest probability of reaching the next value-creating milestone on time, with the right level of control, the lowest avoidable risk, the least stranded capital, and the least unnecessary dilution?” 

For companies with no internal manufacturing ambition and a process that fits an established external platform, a CDMO may be the right answer. For companies with a mature internal GMP team and a strong desire to operate independently, cleanroom rental may be sufficient. For companies that want to retain process control but need a structured, supported, capital-efficient path into GMP, a Biomanufacturing Enablement Organization (BMEO) should be evaluated as a serious alternative. 

Conclusion 

The move from the lab to GMP is where promising science starts to become a clinical product. That transition requires more than space, more than a batch slot, and more than a spreadsheet comparison of quoted prices. It requires a realistic assessment of total cost, quality maturity, execution risk, control, capital efficiency, and strategic flexibility. 

The best model is the one that fits the company’s stage and preserves its ability to learn, adapt, finance, and execute. For early-stage innovators, that often means avoiding premature infrastructure commitments while still building the GMP discipline needed for first-in-human progress. In that context, a BMEO can offer a practical path: infrastructure without the build, support without surrendering control, and a bridge from late preclinical development to first patient, especially where the alternative would be tying scarce capital into specialized equipment, idle space, or fixed infrastructure before the asset is clinically de-risked.